Metabolism Explained · Evidence checked October 12, 2026
PT-141, also called bremelanotide, is a peptide medicine that activates melanocortin receptors. Its prescription form, Vyleesi, is approved for a specific low-desire disorder in premenopausal women. Benefits average out to a modest improvement over placebo, and nausea is common. Human studies in men show an erectile response, but the evidence is much less developed and does not establish a reliable treatment for male low libido or performance anxiety.
PT-141 often gets described as a “libido peptide,” a label that leaves several different questions unanswered. Does it increase sexual interest? Improve erections? Reduce anxiety? And do results in women tell us what to expect in men?
The answer depends on the outcome being measured. Wanting sex, becoming physically aroused, and feeling comfortable during sex overlap, but they are not interchangeable. Understanding those differences makes the research considerably more useful.
What Is PT-141?
PT-141 is the development name for bremelanotide, a synthetic cyclic peptide. For background on the chemistry, our guide to what a polypeptide is explains how amino-acid chains form these molecules.
In the United States, bremelanotide is available by prescription as Vyleesi. Its approved indication is acquired, generalized hypoactive sexual desire disorder, or HSDD, in premenopausal women.
“Acquired” means the low desire developed after a period without that problem. “Generalized” means it occurs across situations or partners. The low desire causes distress, and the diagnosis excludes symptoms explained by another medical or psychiatric condition, relationship problems, or medication effects.
That makes diagnosis consequential. Low interest after starting an antidepressant and persistent HSDD are different clinical questions, even when someone describes both as “low libido.”
How PT-141 Works
Bremelanotide activates melanocortin receptors. Its prescribing information identifies MC1 and MC4 receptor activity as particularly relevant at therapeutic doses. MC4 receptors occur in the central nervous system; MC1 activity helps explain pigmentation effects.
The exact mechanism through which it improves HSDD remains unknown. Descriptions such as “turning on the brain’s desire switch” simplify a pathway that is still incompletely understood.
Sildenafil and tadalafil, commonly known as Viagra and Cialis, help support erections by improving blood flow to the penis during sexual stimulation. Their purpose differs from treating distressing low desire. A person can want sex and have difficulty maintaining an erection, or have normal erectile function and little interest in sex.
A different mechanism gives researchers a reason to investigate a drug. It does not, by itself, establish that the drug will solve a particular person’s problem.
What Did the Trials in Women Actually Find?
The strongest evidence comes from the two RECONNECT phase 3 trials. These randomized, double-blind, placebo-controlled studies followed treatment for 24 weeks and included 1,247 participants in the safety population.
The published pooled analysis found an average advantage over placebo of 0.35 points on the sexual-desire measure and a 0.33-point greater reduction in distress. Those results were statistically significant, but the average difference was modest.
The FDA’s approval announcement also described the results using specific improvement thresholds:
| Outcome | Bremelanotide | Placebo |
|---|---|---|
| Desire score increased by at least 1.2 points | About 25% | About 17% |
| Distress score decreased by at least 1 point | About 35% | About 31% |
| Change in the number of satisfying sexual events | No significant advantage over placebo | |
For the desire threshold, that is approximately eight additional responders per 100 treated compared with placebo. It does not mean everyone else experienced no benefit; a threshold divides a range of responses into two groups.
Nor does statistical significance mean a dramatic change. Some participants benefited, while the average improvement and the difference in responder proportions were limited. Desire and distress improved without a demonstrated increase over placebo in the number of satisfying sexual events.
A subsequent 52-week extension reported sustained improvements and no new safety signals. However, it was open-label and had no placebo group. Participants were also selected from people who completed the earlier trials. That limits what it can establish about long-term effectiveness and tolerability for everyone starting treatment.
Does PT-141 Work in Men?
Human studies have measured erectile effects in men. It would be inaccurate to describe the entire male evidence base as animal research or anecdote.
A 2004 study of subcutaneous PT-141 found statistically significant erectile responses measured with RigiScan, a device that records penile rigidity and tumescence. The research included healthy men and men reporting an inadequate response to sildenafil. This establishes a physiological signal, but it does not establish consistent improvement in everyday sexual satisfaction or desire.
A separate 2005 crossover study involving 19 men found that intranasal PT-141 combined with sildenafil produced a greater erectile response than sildenafil alone. Participants already reported responding to Viagra or Levitra, and the measurements took place with visual sexual stimulation in a controlled setting. The study was small and cannot establish the long-term safety of routinely combining these drugs.
There is also a research-quality concern. A frequently cited trial titled Salvage of Sildenafil Failures With Bremelanotide received an expression of concern from the Journal of Urology in 2023. This is a formal editorial warning about the reliability of a paper, distinct from a retraction. Its results should not be presented as settled evidence.
The practical conclusion is that PT-141 has shown biological activity in men, while the size, consistency, and clinical usefulness of its benefits remain uncertain. Vyleesi’s approval does not cover men, and the early studies do not establish a standard male treatment regimen.
PT-141 Side Effects and Safety Limits
The pooled placebo-controlled Vyleesi trials reported:
| Adverse reaction | Vyleesi | Placebo |
|---|---|---|
| Nausea | 40.0% | 1.3% |
| Flushing | 20.3% | 0.3% |
| Injection-site reactions | 13.2% | 8.4% |
| Headache | 11.3% | 1.9% |
| Vomiting | 4.8% | 0.2% |
These are proportions of participants reporting reactions during the trials, not the probability of a reaction after each injection. Adverse reactions led 18% of Vyleesi participants to discontinue, compared with 2% on placebo.
Bremelanotide can temporarily raise blood pressure and lower heart rate. Vyleesi is contraindicated with uncontrolled hypertension or known cardiovascular disease. Pigmentation changes may persist after treatment stops.
Medication review also matters. It can affect absorption of oral drugs, including oral naltrexone used for alcohol or opioid addiction. People who are pregnant or may become pregnant need specific prescribing advice. These are reasons to assess suitability before treatment, even when the main goal sounds as straightforward as improving desire.
How Prescription Vyleesi Is Used
The labeled dose is 1.75 mg, delivered under the skin with a prefilled autoinjector. It is used as needed at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours; more than eight monthly doses is not recommended. Treatment should stop after eight weeks without symptom improvement.
This describes the approved prescription product and population. It is not a dosing protocol for men, nasal sprays, or powders sold for research. Different routes and formulations cannot be assumed to deliver equivalent exposure.
Low Desire, Erectile Difficulty, and Anxiety Need Different Evaluations
A useful starting point is to describe the difficulty precisely:
- Low desire: little interest in sexual activity, including outside situations where performance is expected.
- Erectile difficulty: interest is present, but getting or maintaining an erection is difficult.
- Performance anxiety: worry, self-monitoring, or fear of disappointing a partner interferes with the experience.
These can occur together. A clinician may review medication effects, physical health, hormone-related symptoms, and psychological or relationship factors. NIDDK includes counseling for anxiety or stress among treatment options for erectile dysfunction, along with medication review and established erectile treatments.
PT-141’s effects in a sexual-function study do not demonstrate that it treats anxiety. Someone whose main problem is anxious self-monitoring should not assume that stronger arousal will resolve it.
Prescription Medicine and Research Peptides Are Different Products
FDA approval applies to a specific drug product, its manufacturing standards, and its approved use. It does not automatically extend to every vial or spray labeled “PT-141.”
A clinician prescribing an approved medicine for an unapproved purpose is practicing off-label prescribing. That differs from purchasing an unapproved research product. Compounded medicines are also not FDA-approved; the FDA does not review their safety, effectiveness, and quality before marketing as it does for approved drugs.
A laboratory purity claim alone does not establish clinical effectiveness, sterility, or suitability for injection. Readers evaluating a product should distinguish evidence about the molecule from evidence about the actual product being offered.
Frequently Asked Questions
Is PT-141 a Testosterone Treatment?
No. Bremelanotide acts on melanocortin receptors and does not replace testosterone. Suspected testosterone deficiency requires its own evaluation; a response to a sexual-function drug would not diagnose or exclude it.
Is PT-141 a Weight-Loss Peptide?
Its established clinical use concerns HSDD, not weight management. Sharing the broad “peptide” category with semaglutide does not imply equivalent effects. Our explanation of semaglutide’s peptide structure describes why the specific molecule and receptor target matter.
Does PT-141 Last All Weekend?
A reliable all-weekend effect has not been established. The Vyleesi label states that the duration of efficacy after a dose is unknown. Drug elimination time and duration of a noticeable benefit are different measurements.
Can PT-141 Help If Viagra Has Not Worked?
Early research provides a reason to investigate that possibility. It does not establish a dependable rescue treatment. Reviewing the original diagnosis, medication use, and established alternatives remains important before moving to a treatment with less certain evidence.
References
- Vyleesi prescribing information, DailyMed. Indication, mechanism, adverse-reaction table, dosing, warnings, and duration-of-effect limitations.
- U.S. Food and Drug Administration, Vyleesi approval announcement. June 21, 2019; FDA release distributed through PR Newswire. Response thresholds and trial interpretation.
- Kingsberg and colleagues, two randomized phase 3 RECONNECT trials. Obstetrics & Gynecology, 2019. DOI: 10.1097/AOG.0000000000003500.
- Long-term safety and efficacy of bremelanotide for HSDD. Obstetrics & Gynecology, 2019. DOI: 10.1097/AOG.0000000000003514.
- Rosen and colleagues, subcutaneous PT-141 in healthy men and men reporting inadequate sildenafil response. International Journal of Impotence Research, 2004. DOI: 10.1038/sj.ijir.3901200.
- Diamond and colleagues, intranasal PT-141 with sildenafil in men with erectile dysfunction. Urology, 2005. DOI: 10.1016/j.urology.2004.10.060.
- Expression of concern regarding the sildenafil-failure trial. Journal of Urology, 2023. DOI: 10.1097/JU.0000000000003117.
- MedlinePlus, bremelanotide injection. Patient information on use, precautions, and interactions.
- NIDDK, treatment for erectile dysfunction. Evaluation of contributing factors and treatment options.
- FDA, understanding off-label use, and compounding questions and answers. Product approval and prescribing distinctions.